Sponsored by:

Duke MMIL designs novel SPECT/CT system for 3D breast imaging

Jul 17, 2007
2007 07 17 14 38 39 706
2007 07 17 14 38 39 706
Image courtesy of Duke University Medical Center Multi-Modality Imaging Lab.

close

Latest in Molecular Imaging
Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.
Case report: Pluvicto as a first-line treatment in late-stage prostate cancer
September 26, 2025
Prostate Imaging
Lantheus and GEHC to launch PET agent for prostate imaging in Japan
September 24, 2025
Your faster way to answers with Symbia Pro.specta
Sponsored
Your faster way to answers with Symbia Pro.specta
September 3, 2025
Images in a 62-year-old woman who presented for screening. (A) Image from DBT screening (the synthesized 2D mediolateral oblique view of the left breast is shown) at year on was interpreted as negative and showing heterogeneously dense breast. (B) Image from molecular breast imaging screening (mediolateral oblique view) at year one reveals a 0.9-cm non-mass focal area of uptake in the left breast (arrow). (C) Targeted ultrasound scan (transverse image) shows a suspicious mass in the 3-o’clock position of the left breast, 4 cm from the nipple. Ultrasound-guided core biopsy and lumpectomy revealed a 0.9-cm grade 2 invasive ductal carcinoma, an estrogen receptor–negative, progesterone receptor–negative, human epidermal growth factor receptor 2–negative lesion, with two sentinel nodes negative (N0).
Adding MBI to DBT finds more breast cancers
September 23, 2025
Related Stories
2007 07 17 15 08 50 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 07 17 14 32 28 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 06 25 10 54 15 706
Molecular Imaging
Studies link Alzheimer's to beta-amyloid and potential for new ligand
Fast imaging with Symbia Pro.specta SPECT/CT
Sponsor Content
Fast imaging with Symbia Pro.specta SPECT/CT
More in Molecular Imaging
Case report: Pluvicto as a first-line treatment in late-stage prostate cancer
Since 1996, the patient continually declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland.
September 26, 2025
Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.
Lantheus and GEHC to launch PET agent for prostate imaging in Japan
By AuntMinnie.com staff writers
GEHC will draw on its manufacturing network and R&D expertise following its acquisition in March 2025 of Nihon Medi-Physics.
September 24, 2025
Prostate Imaging
NorthStar partners with Univ. of Wisconsin on radiopharma research
By AuntMinnie.com staff writers
The multiyear project furthers the goal of turning southern Wisconsin into a nuclear medicine hub.
September 23, 2025
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
Adding MBI to DBT finds more breast cancers
By Amerigo Allegretto
Adding molecular breast imaging (MBI) to DBT screening leads to more invasive cancers detected in women with dense breasts.
September 23, 2025
Images in a 62-year-old woman who presented for screening. (A) Image from DBT screening (the synthesized 2D mediolateral oblique view of the left breast is shown) at year on was interpreted as negative and showing heterogeneously dense breast. (B) Image from molecular breast imaging screening (mediolateral oblique view) at year one reveals a 0.9-cm non-mass focal area of uptake in the left breast (arrow). (C) Targeted ultrasound scan (transverse image) shows a suspicious mass in the 3-o’clock position of the left breast, 4 cm from the nipple. Ultrasound-guided core biopsy and lumpectomy revealed a 0.9-cm grade 2 invasive ductal carcinoma, an estrogen receptor–negative, progesterone receptor–negative, human epidermal growth factor receptor 2–negative lesion, with two sentinel nodes negative (N0).
Radiation oncologists put RefleXion’s X1 system to the test
By Will Morton
A pilot study demonstrates the potential feasibility of using RefleXion's X1 unit in patients with prostate cancer.
September 19, 2025
An example of a typical BgRT plan: A) PET scan on diagnostic PET/CT and B) X1 PET-Linac for patient #15 with a PET avid rib metastasis with GTV size= 3.1 cc, PTV = GTV + 5mm, BTZ (biological tracking zone) = PTV + 5 mm, AC = 14.33 kBq/mL and NTS = 21.04. Red, magenta, and green contours represent GTV, PTV, and BTZ. C) Dose distribution and D) bounded-DVH of a BgRT plan are displayed for the same patient. The bounded Dose-Volume Histogram (DVH) models variations in BgRT delivery, encompassing fluctuation in target background signal variation, target localization and dose delivery uncertainties.
4 nuclear medicine societies publish consensus statement on MPI
By AuntMinnie.com staff writers
Four nuclear medicine societies have issued a new guideline for F-18 flurpiridaz PET myocardial perfusion imaging (MPI).
September 18, 2025
Nuclear Medicine Gamma Camera 400
Contineum Therapeutics highlights data from PET drug trial
By AuntMinnie.com staff writers
Contineum Therapeutics has reported successful results from its Pipe-791 Phase 1b PET trial.
September 18, 2025
Pet Scan Thumbnail
Ontario invests 18M Canadian dollars to expand medical isotope production
By AuntMinnie.com staff writers
The investment will expand operations to 24 hours a day, seven days a week.
September 17, 2025
Isotopes1
SNMMI highlights study results of new targeted cancer therapy
By AuntMinnie.com staff writers
Three patients with solitary fibrous tumors achieved a near-complete response after treatment.
September 17, 2025
2025 09 17 Y90 Fapi 46 400
PET/MRI shows promise in rectal cancer
By Will Morton
F-18 FDG-PET/MRI provided superior detection of lymph nodes and tumor deposits over standard imaging.
September 15, 2025
Rectal Cancer
Neuroinflammation persists for 2 years in long COVID
By Will Morton
Increased inflammatory activity was found on TSPO-PET in some individuals with post-COVID syndrome.
September 12, 2025
2025 09 12 Long Covid Brain Images Thumbnail
The rise of theranostics: Part 6 -- Private practices pivot to clinical trials
By Liz Carey
Regional capacity slowly builds for burgeoning demand, but data is lacking on nuclear medicine and theranostics needs across the U.S.
September 12, 2025
Rise Of Thernostics Part 6 Thumbnail
Page 1 of 614
Next Page